SCHEMBL19904760

SCHEMBL19904760

CCCCOP(OCCCC)Oc1ccc2ccccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CETP P11597 1/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ CYP2A6 P11509 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ PPARG P37231 3/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ PPARA Q07869 2/20 0.41
▸ AGXT P21549 2/20 0.41
▸ DRD3 P35462 1/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.40
▸ GPBAR1 Q8TDU6 1/20 0.40
▸ CYSLTR2 Q9NS75 1/20 0.40
▸ CYSLTR1 Q9Y271 1/20 0.40
▸ LTA4H P09960 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20710755 0.84 CYP2A6 (0.48) CETPCYP1A2CYP2A6TDP1KDM4E
SCHEMBL445915 0.82 LTA4H (0.53) CYP1A2TDP1MAPK1CYP3A4CYP2C9
SCHEMBL11748365 0.82 NPC1 (0.45) CYP1A2CYP2A6TDP1KDM4EMAPK1
SCHEMBL430999 0.79 LTA4H (0.53) CYP1A2TDP1MAPK1CYP3A4CYP2C9
SCHEMBL29666114 0.78 TDP1 (0.68) CYP1A2CYP2A6TDP1KDM4EMAPK1
SCHEMBL470925 0.78 TDP1 (0.68) CYP1A2CYP2A6TDP1KDM4EMAPK1
SCHEMBL3960261 0.78 CYP2A6 (0.56) CYP1A2CYP2A6TDP1KDM4EMAPK1
SCHEMBL19904727 0.78 MAOB (0.40) CYP1A2CYP2C9CYP2C19LTA4H
SCHEMBL19904747 0.78 MAOB (0.39) CYP1A2KDM4ECYP2C19RAB9ALTA4H
SCHEMBL991869 0.77 LTA4H (0.53) MAPK1CYP3A4DRD3HRH3LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097428-B1 BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES MGP BIOTECHNOLOGIES INC (US) 2018-02-28 — — EP disclosed
Send feedback